Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis

被引:27
作者
Alves Lima, Marcos Venicio
Ferreira, Francisco Valdeci
Bulcao Macedo, Francisco Yuri
de Castro Brito, Gerly Anne
Ribeiro, Ronaldo Albuquerque
机构
[1] Univ Fed Ceara, Fac Med, Ctr Biomed, BR-60430270 Fortaleza, Ceara, Brazil
[2] Canc Inst Ceara, Dept Surg, Div Urol, Fortaleza, Ceara, Brazil
[3] Canc Inst Ceara, Dept Pathol, Fortaleza, Ceara, Brazil
[4] Univ Fed Ceara, Fac Med, Dept Physiol & Pharmacol, Fortaleza, Ceara, Brazil
[5] Univ Fed Ceara, Fac Med, Dept Morphol, Fortaleza, Ceara, Brazil
[6] Canc Inst Ceara, Dept Clin Oncol, Fortaleza, Ceara, Brazil
关键词
ifosfamide; hemorrhagic cystitis; mesna; histopathology;
D O I
10.1007/s00280-006-0307-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Hemorrhagic cystitis (HC) is a limiting side effect of chemotherapy with ifosfamide (IFS). Mesna is the drug of choice for prevention of HC. In this study, we analyzed cystoscopic and histological changes present in bladders of patients using IFS with mesna prophylaxis. Thirty-three patients selected for IFS plus three doses of mesna chemotherapy regime were assigned at random to two groups: Group I or reference group consisted of 18 patients yet untreated. Group II consisted of 15 patients in whom urinalysis and cystoscopy plus vesical biopsy were performed only 24 h after receiving the last dose of IFS. The cystoscopic and histological findings were used as parameters for evaluating the results. For the former the criterion adopted was macroscopic vesical changes in accordance with Gray's criteria. Histological analyses were performed by evaluation method especially adapted to this study. Even under treatment with three doses of mesna, 66.7% of patients presented cystoscopic alterations and 100% showed bladder mucosa microscopic alterations such as edema, exocytosis, and hemorrhage. The standard protocol used for prevention of IFS-induced HC with three doses of mesna does not completely prevent bladder damage. The histopathological criteria used in this study for observation of inflammatory events allowed staging the intensity of IFS-induced urothelial and mucosal injury.
引用
收藏
页码:643 / 650
页数:8
相关论文
共 22 条
[1]
IFOSFAMIDE - PHARMACOLOGY, SAFETY AND THERAPEUTIC POTENTIAL [J].
BRADE, WP ;
HERDRICH, K ;
VARINI, M .
CANCER TREATMENT REVIEWS, 1985, 12 (01) :1-47
[2]
THE DEVELOPMENT OF MESNA FOR REGIONAL DETOXIFICATION [J].
BROCK, N ;
POHL, J .
CANCER TREATMENT REVIEWS, 1983, 10 :33-&
[3]
CLINICAL OVERVIEW OF MESNA [J].
BURKERT, H .
CANCER TREATMENT REVIEWS, 1983, 10 :175-181
[4]
CYCLOPHOSPHAMIDE CYSTITIS - IDENTIFICATION OF ACROLEIN AS THE CAUSATIVE AGENT [J].
COX, PJ .
BIOCHEMICAL PHARMACOLOGY, 1979, 28 (13) :2045-2049
[5]
IFOSFAMIDE MESNA - A REVIEW OF ITS ANTINEOPLASTIC ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN CANCER [J].
DECHANT, KL ;
BROGDEN, RN ;
PILKINGTON, T ;
FAULDS, D .
DRUGS, 1991, 42 (03) :428-467
[6]
Comparison of the uroprotective efficacy of mesna and HBO treatments in cyclophosphamide-induced hemorrhagic cystitis [J].
Etlik, O ;
Tomur, A ;
Deveci, S ;
Piskin, I ;
Pekcan, M .
JOURNAL OF UROLOGY, 1997, 158 (06) :2296-2299
[7]
URINARY-BLADDER COMPLICATIONS WITH CYCLOPHOSPHAMIDE THERAPY [J].
FOAD, BSI ;
HESS, EV .
ARCHIVES OF INTERNAL MEDICINE, 1976, 136 (05) :616-619
[8]
GOMES TNA, 1995, BRAZ J MED BIOL RES, V28, P1103
[9]
EVALUATION OF MISOPROSTOL CYTOPROTECTION OF THE BLADDER WITH CYCLOPHOSPHAMIDE (CYTOXAN) THERAPY [J].
GRAY, KJ ;
ENGELMANN, UH ;
JOHNSON, EH ;
FISHMAN, IJ .
JOURNAL OF UROLOGY, 1986, 136 (02) :497-500
[10]
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants [J].
Hensley, ML ;
Schuchter, LM ;
Lindley, C ;
Meropol, NJ ;
Cohen, GI ;
Broder, G ;
Gradishar, WJ ;
Green, DM ;
Langdon, RJ ;
Mitchell, B ;
Negrin, R ;
Szatrowski, TP ;
Thigpen, JT ;
Von Hoff, D ;
Wasserman, TH ;
Winer, EP ;
Pfister, DG .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3333-3355